Sally C. Pipes
Commentary
If Health Insurance Premiums Rise Next Year, Blame Democrats
In the ongoing government shutdown saga, Democrats continue to cast themselves as defenders of affordable health insurance… Premiums have been on a steady upward trajectory for more than a decade. Obamacare’s own diktats are why premiums have risen. Read the op-ed here.
Commentary
How Obamacare Set In Motion Today’s Premium Crisis
Democrats are panicking about a looming 75% average increase in the out-of-pocket cost of insurance premiums next year for the roughly 6% of the population that shops for coverage on Obamacare’s exchanges. Their panic led them to shut down the government at the end of September. The increase is a ...
Commentary
Trump Delivers Mixed Results on Health Reform
Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure. But the results of his efforts to date have been mixed. Consider Trump’s approach to prescription drug prices. ...
Commentary
Patients Can’t Wait for Federal Action on Knock-Off Medicines
For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...
Commentary
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Commentary
Shut down the enhanced Obamacare subsidies, not the government
Is it worth shutting down the government to keep billions in federal cash flowing to health insurers? That’s a question Republicans should be asking Democrats every chance they get. The minority party has brought business in Washington to a halt as part of a wrongheaded strategy to obscure the out-of-control ...
Commentary
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
Commentary
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Commentary
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank. According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase ...
Commentary
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...
If Health Insurance Premiums Rise Next Year, Blame Democrats
In the ongoing government shutdown saga, Democrats continue to cast themselves as defenders of affordable health insurance… Premiums have been on a steady upward trajectory for more than a decade. Obamacare’s own diktats are why premiums have risen. Read the op-ed here.
How Obamacare Set In Motion Today’s Premium Crisis
Democrats are panicking about a looming 75% average increase in the out-of-pocket cost of insurance premiums next year for the roughly 6% of the population that shops for coverage on Obamacare’s exchanges. Their panic led them to shut down the government at the end of September. The increase is a ...
Trump Delivers Mixed Results on Health Reform
Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure. But the results of his efforts to date have been mixed. Consider Trump’s approach to prescription drug prices. ...
Patients Can’t Wait for Federal Action on Knock-Off Medicines
For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Shut down the enhanced Obamacare subsidies, not the government
Is it worth shutting down the government to keep billions in federal cash flowing to health insurers? That’s a question Republicans should be asking Democrats every chance they get. The minority party has brought business in Washington to a halt as part of a wrongheaded strategy to obscure the out-of-control ...
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank. According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase ...
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...
